Select Equity Group
TXG icon

Select Equity Group’s 10x Genomics TXG Stock Holding History

Select Equity Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-136,867
Closed -$10.4M – 174
2022
Q1 		$10.4M Buy
+136,867
New +$12M 0.03% 116

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Select Equity Group's TXG Position: Q2 2022 in Review

Select Equity Group sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 136,867 shares — an estimated $10.4M sold.

Select Equity Group first reported a position in TXG in Q1 2022 and held it in 1 quarter. The position peaked at $10.4M in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Select Equity Group reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Select Equity Group sold 136,867 10x Genomics shares in Q2 2022, an estimated $10.4M.
  • Select Equity Group first reported a position in 10x Genomics in Q1 2022 and held it in 1 quarter.
  • Select Equity Group's 10x Genomics position peaked at $10.4M in Q1 2022.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Select Equity Group's 13F filing for Q2 2022, filed 15 Aug 2022.